93 related articles for article (PubMed ID: 17001530)
21. [Extraction, purification technology and antineoplastic effects of solamargine].
Tang Z; Zhang Y; Li N; Xu L; Zhao B; Xiao W; Wang Z; Bi Y
Zhongguo Zhong Yao Za Zhi; 2011 Aug; 36(16):2192-5. PubMed ID: 22097327
[TBL] [Abstract][Full Text] [Related]
22. Effects of naturally occurring glucosides, solasodine glucosides, ginsenosides and parishin derivatives on multidrug resistance of lymphoma cells and leukocyte functions.
Berek L; Szabó D; Petri IB; Shoyama Y; Lin YH; Molnár J
In Vivo; 2001; 15(2):151-6. PubMed ID: 11317520
[TBL] [Abstract][Full Text] [Related]
23. Anticancer Properties of Solamargine: A Systematic Review.
Kalalinia F; Karimi-Sani I
Phytother Res; 2017 Jun; 31(6):858-870. PubMed ID: 28383149
[TBL] [Abstract][Full Text] [Related]
24. Trans-sialidase and mucins of Trypanosoma cruzi: an important interplay for the parasite.
Giorgi ME; de Lederkremer RM
Carbohydr Res; 2011 Sep; 346(12):1389-93. PubMed ID: 21645882
[TBL] [Abstract][Full Text] [Related]
25. Effects of a marine serine protease inhibitor on viability and morphology of Trypanosoma cruzi, the agent of Chagas disease.
de Almeida Nogueira NP; Morgado-Díaz JA; Menna-Barreto RF; Paes MC; da Silva-López RE
Acta Trop; 2013 Oct; 128(1):27-35. PubMed ID: 23770204
[TBL] [Abstract][Full Text] [Related]
26. Developmental toxicology of solamargine and solasonine glycoalkaloids in frog embryos.
Blankemeyer JT; McWilliams ML; Rayburn JR; Weissenberg M; Friedman M
Food Chem Toxicol; 1998 May; 36(5):383-9. PubMed ID: 9662413
[TBL] [Abstract][Full Text] [Related]
27. Mexican Trypanosoma cruzi isolates: in vitro susceptibility of epimastigotes to anti-trypanosoma cruzi drugs and metacyclic forms to complement-mediated lysis.
León-Pérez F; Gómez-Garcia L; Alejandre-Aguilar R; López R; Monteón VM
Vector Borne Zoonotic Dis; 2007; 7(3):330-6. PubMed ID: 17760512
[TBL] [Abstract][Full Text] [Related]
28. The rhamnose moiety of solamargine plays a crucial role in triggering cell death by apoptosis.
Chang LC; Tsai TR; Wang JJ; Lin CN; Kuo KW
Biochem Biophys Res Commun; 1998 Jan; 242(1):21-5. PubMed ID: 9439603
[TBL] [Abstract][Full Text] [Related]
29. Phospholipase A1: a novel virulence factor in Trypanosoma cruzi.
Belaunzarán ML; Wilkowsky SE; Lammel EM; Giménez G; Bott E; Barbieri MA; de Isola EL
Mol Biochem Parasitol; 2013 Feb; 187(2):77-86. PubMed ID: 23275096
[TBL] [Abstract][Full Text] [Related]
30. Conformational restriction of aryl thiosemicarbazones produces potent and selective anti-Trypanosoma cruzi compounds which induce apoptotic parasite death.
Magalhaes Moreira DR; de Oliveira AD; Teixeira de Moraes Gomes PA; de Simone CA; Villela FS; Ferreira RS; da Silva AC; dos Santos TA; Brelaz de Castro MC; Pereira VR; Leite AC
Eur J Med Chem; 2014 Mar; 75():467-78. PubMed ID: 24561675
[TBL] [Abstract][Full Text] [Related]
31. Ruthenium complexes endowed with potent anti-Trypanosoma cruzi activity: Synthesis, biological characterization and structure-activity relationships.
Donnici CL; Araújo MH; Oliveira HS; Moreira DR; Pereira VR; de Assis Souza M; de Castro MC; Leite AC
Bioorg Med Chem; 2009 Jul; 17(14):5038-43. PubMed ID: 19539479
[TBL] [Abstract][Full Text] [Related]
32. Solamargine production by a fungal endophyte of Solanum nigrum.
El-Hawary SS; Mohammed R; AbouZid SF; Bakeer W; Ebel R; Sayed AM; Rateb ME
J Appl Microbiol; 2016 Apr; 120(4):900-11. PubMed ID: 26811095
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of a series of alpha-pyrone derivatives against Leishmania (L.) infantum and Trypanosoma cruzi.
Tempone AG; Ferreira DD; Lima ML; Costa Silva TA; Borborema SET; Reimão JQ; Galuppo MK; Guerra JM; Russell AJ; Wynne GM; Lai RYL; Cadelis MM; Copp BR
Eur J Med Chem; 2017 Oct; 139():947-960. PubMed ID: 28881289
[TBL] [Abstract][Full Text] [Related]
34. Ultrastructural alterations and growth inhibition of Trypanosoma cruzi and Leishmania major induced by Bothrops jararaca venom.
Gonçalves AR; Soares MJ; de Souza W; DaMatta RA; Alves EW
Parasitol Res; 2002 Jul; 88(7):598-602. PubMed ID: 12107450
[TBL] [Abstract][Full Text] [Related]
35. Trypanosoma cruzi: roles for perforin-dependent and perforin-independent immune mechanisms in acute resistance.
Nickell SP; Sharma D
Exp Parasitol; 2000 Apr; 94(4):207-16. PubMed ID: 10831388
[TBL] [Abstract][Full Text] [Related]
36. In vitro activity of N-benzenesulfonylbenzotriazole on Trypanosoma cruzi epimastigote and trypomastigote forms.
Becerra MC; Guiñazú N; Hergert LY; Pellegrini A; Mazzieri MR; Gea S; Albesa I
Exp Parasitol; 2012 May; 131(1):57-62. PubMed ID: 22425748
[TBL] [Abstract][Full Text] [Related]
37. Trypanosoma cruzi: isolation of cloned strains and characterization of their infectivity.
Tanuri A; de Andrade PP; de Almeida DF
J Parasitol; 1985 Aug; 71(4):397-402. PubMed ID: 3928860
[TBL] [Abstract][Full Text] [Related]
38. Kinetic analysis of antigen-specific immune responses in resistant and susceptible mice during infection with Trypanosoma cruzi.
Hoft DF; Lynch RG; Kirchhoff LV
J Immunol; 1993 Dec; 151(12):7038-47. PubMed ID: 8258708
[TBL] [Abstract][Full Text] [Related]
39. Control mechanisms of tubulin gene expression in Trypanosoma cruzi.
da Silva RA; Bartholomeu DC; Teixeira SM
Int J Parasitol; 2006 Jan; 36(1):87-96. PubMed ID: 16233898
[TBL] [Abstract][Full Text] [Related]
40. Amastigote and epimastigote stage-specific components of Trypanosoma cruzi characterized by using monoclonal antibodies. Purification and molecular characterization of an 83-kilodalton amastigote protein.
Pan AA; McMahon-Pratt D
J Immunol; 1989 Aug; 143(3):1001-8. PubMed ID: 2501384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
